A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
← catalyst calendarNCT03165734 · readout in 47 d
Sponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →. With PSI CRO.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
407actual
Sites
207
Countries
Australia, Belarus, Bosnia and Herzegovina +21
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2017-06-26 | actual | When the study began enrolling |
| Primary completion | 2026-10-05 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-13 | estimated | The whole study's end, after follow-up |
| First posted | 2017-05-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Primary Myelofibrosis
- Post-polycythemia Vera Myelofibrosis
- Post-essential Thrombocythemia Myelofibrosis
Interventions
- Drug: Pacritinib
- Drug: Physician's Choice medications — also filed as corticosteroids, hydroxyurea, danazol, low-dose ruxolitinib
Primary outcomes
what the primary-completion date above is the date OFSpleen volume
measured From baseline at 24 weeks
Total Symptom Score (TSS) (excluding tiredness)
measured From baseline at Week 24
Publications
- PMID 33232476 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed